Your browser doesn't support javascript.
loading
The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone.
Tran, Linh N K; Kichenadasse, Ganessan; Morel, Katherine L; Lavranos, Tina C; Klebe, Sonja; Lower, Karen M; Ormsby, Rebecca J; Elliot, David J; Sykes, Pamela J.
Afiliación
  • Tran LNK; Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Adelaide, South Australia khaclinh@gmail.com linh.tran@flinders.edu.au khaclinh@ump.edu.vn.
  • Kichenadasse G; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam.
  • Morel KL; Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Adelaide, South Australia.
  • Lavranos TC; Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Adelaide, South Australia.
  • Klebe S; Bionomics Ltd, Thebarton, South Australia.
  • Lower KM; Department of Anatomical Pathology, Flinders University and Medical Centre, Adelaide, South Australia.
  • Ormsby RJ; Molecular Medicine and Pathology, Flinders University and Medical Centre, Adelaide, South Australia.
  • Elliot DJ; Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Adelaide, South Australia.
  • Sykes PJ; Clinical Pharmacology, Flinders University and Medical Centre, Bedford Park, Adelaide, South Australia.
In Vivo ; 33(1): 99-108, 2019.
Article en En | MEDLINE | ID: mdl-30587609
BACKGROUND/AIM: The hypoglycemic drug metformin (MET) and the anti-epileptic drug valproic acid (VPA) have individually shown anti-tumor effects in prostate cancer in vitro. The present study intended to investigate the efficacy of the combination of MET and VPA in prostate cancer treatment in a pre-clinical xenograft model. MATERIALS AND METHODS: Prostate cancer cell lines (LNCaP and PC-3) were inoculated under the skin of BALB/c nude mice. The mice were treated with 200 µl/ml MET and/or 0.4% (w/v) VPA diluted in drinking water, or with vehicle control, and were monitored until the tumor volume reached 2,000 mm3 Evaluation of toxicity of the drug combination was determined in liver and kidney by histology. RESULTS: In both LNCaP and PC-3 xenografts, MET combined with VPA significantly reduced tumor growth during the first 4 weeks following treatment, and delayed the time-to-tumor volume of 2,000 mm3 by 90 days, as compared to MET or to VPA alone, and to vehicle control. There was no significant difference in total mouse weight, liver or kidney morphology in response to combination treatment (MET+VPA) compared to MET or VPA alone and vehicle control. CONCLUSION: The combination treatment of MET with VPA is more effective at slowing prostate tumor growth in vivo compared to either drug alone, in mouse xenografts. These pre-clinical results support previous in vitro data and also demonstrate the low toxicity of the combination of these drugs, suggesting that this may be a potential new therapy to be investigated in clinical trials for prostate cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Ácido Valproico / Metformina Límite: Animals / Humans / Male Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Ácido Valproico / Metformina Límite: Animals / Humans / Male Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Grecia